Assignee
GLUETACS THERAPEUTICS SHANGHAI CO LTD
CN·0 granted patents·6 pending applications·0 citations·filing 2022–2025
Top patents by PatentIndex Score
6 records- 0158US2024425475A1Compound based on quinazoline-substituted glutarimide skeleton and use thereofGLUETACS THERAPEUTICS SHANGHAI CO LTD·Filed 2024·Application pending·0 cites
- 0253US2025320193A1Oxoisoindolinyl substituted piperidinedione derivative and use thereofGLUETACS THERAPEUTICS SHANGHAI CO LTD·Filed 2025·Application pending·0 cites
- 0353US2025144223A1Protein degradation compound based on nampt target protein and application thereofGLUETACS THERAPEUTICS SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 0452US2026028326A1Compound based on isoindoline-substituted glutarimide backbone and use thereofGLUETACS THERAPEUTICS SHANGHAI CO LTD·Filed 2023·Application pending·0 cites
- 0548US2025243210A1Crbn e3 ligase ligand compound, protein degrader developed based thereon and their applicationsGLUETACS THERAPEUTICS SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 0637US2025268906A1Molecular glue compound based on cereblon protein design and use thereofGLUETACS THERAPEUTICS SHANGHAI CO LTD·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when GLUETACS THERAPEUTICS SHANGHAI CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →